Resolutions at the Annual General Meeting in Biotage AB on April 25, 2013

At the Annual General Meeting held in Biotage AB (Reg. No. 556539-3138) on April
25, 2013, the following resolutions were passed, among others.

Appropriation of the company’s result

The General Meeting resolved a dividend of SEK 0.50 per share, which in
aggregate is a dividend in the amount of no higher than SEK 34,930,665.

Record date for dividend was resolved to be Tuesday, 30 April 2013.

Board of Directors. Auditors etc.

The General Meeting resolved that the board should be composed of six board
members (with no deputy board members).

The General Meeting resolved to re-elect Ove Mattsson, Thomas Eklund, Karolina
Lawitz, Nils Olof Björk and Anders Walldov as Board members. The General Meeting
resolved to elect Peter Ehrenheim as new Board member. The General Meeting
resolved to appoint Ove Mattsson Chairman of the Board.

The General Meeting resolved to re-elect the auditing firm Deloitte AB, with
Marcus Sörlander as auditor in charge, as the company’s auditor for the period
until the end of the General Meeting to be held 2014.

The General Meeting resolved that a fee of SEK 1,220,000 shall be paid to the
Board of Directors for the period up to and including the Annual General Meeting
2012 to be distributed as follows: the Chairman shall receive SEK 420,000 and
each of the other Board members elected by the General Meeting who are not
employed by the company shall receive SEK 160,000. In addition to that, a fee
shall be paid to the members of the Auditing Committee of an aggregate of not
more than SEK 100,000, whereof the Chairman shall receive SEK 50,000 and the two
other members SEK 25,000 each.

Nomination Committee

The General Meeting resolved that the Chairman of the Board of Directors shall
be appointed as member of the Nomination Committee and shall be instructed to
appoint, in consultation with the (by voting rights) the three major
shareholders of the company as per September 1, 2013, another three members. The
names of such members shall be published no later than six months before the
Annual General Meeting 2014. The Nomination Committee shall appoint one of the
members to be the Chairman of the Committee. The Chairman of the Board may not
be appointed Chairman of the Nomination Committee.

The Nomination Committee shall, before the Annual General Meeting 2014, prepare
proposals for the election of Chairman and other members of the Board of
Directors, the election of Chairman of the Annual General Meeting, the election
of auditors, the determination of fees and matters pertaining thereto.

Resolution on guidelines for compensation for the executive management

The General Meeting resolved to adopt guidelines for compensation for the
executive management in accordance with the proposal by the Board of Directors.

Resolutions on a reduction of the share capital through cancellation of treasury
shares and a bonus issue

The General Meeting resolved to reduce the company’s share capital of SEK
4,141,137.50 through cancellation of 3,934,375 shares, without reimbursement to
the shareholders.

The General Meeting resolved to increase the company’s share capital through a
bonus issue which will increase the share capital with with SEK 4,191,679.80,
without the issue of new shares.

The General Meeting resolved to authorize the Board of Directors, or a person
appointed by the Board, to implement any minor adjustments to the Meeting’s
resolution that may be necessary in connection with registration with the
Swedish Companies Registration Office and Euroclear.

Authorization for the Board of Directors to issue shares and/or convertibles

The General Meeting resolved to authorize the Board to issue shares and/or
convertibles with or without deviation from the shareholders’ pre-emption
rights. The Board of Directors shall have the right to resolve that the shares
and/or the convertibles shall be paid in kind or otherwise be subject to
conditions referred to in Chapter 2 Section 5 second paragraph 1-3 and 5 of the
Swedish Companies Act or that the shares and/or the convertibles shall be
subscribed for with a right of set-off. The Board’s resolutions may result in an
increase of the number of shares in the company by not more than 6,900,000
shares in total.

Authorization for the board of directors to acquire and transfer own shares

The General Meeting resolved to authorize the board of directors to acquire and
transfer own shares on NASDAQ OMX Stockholm substantially in accordance with
following:

1.      The authorisation may be utilised on one or more occasions, however not
longer than until the 2014 annual general meeting.

2.      The company may purchase at the most so many shares that the company’s
holding of own shares after the purchase amounts to a maximum of one-tenth of
all the shares in the company.

3.      Acquisitions and transfers of shares may only take place at a price
within the price interval at any time recorded on the NASDAQ OMX Stockholm, and
this shall refer to the interval between the highest buying price and the lowest
selling price.

Uppsala, April 25, 2013

Biotage AB (publ)

     The Board of Directors

Contact:
Torben Jörgensen, President and CEO
Tel: +46 707 49 05 84, torben.jorgensen@biotage.com

Biotage discloses the information provided herein pursuant to the Swedish
Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The
information was submitted for publication at 17.30 on 25 April 2013.

About Biotage
Biotage offers solutions, knowledge and experience in the areas of analytical
chemistry, medicinal chemistry, separation and purification. The customers
include pharmaceutical and biotech companies, companies within the food industry
and leading academic institutes. The company is headquartered in Uppsala and has
offices in the US, UK, China and Japan. Biotage has approx. 290 employees and
had sales of 463 MSEK in 2012. Biotage is listed on the NASDAQ OMX Nordic
Stockholm stock exchange. Website: www.biotage.com